Holen Sie sich die Stockscreener-App
11.05
6.45%
0.67
Handel nachbörslich:
11.11
0.06
+0.54%
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
Helus Pharma Inc. (CN:HELP) Rallies 10.53% as Positive Momentum Sharpens Investor Focus - kalkine.ca
What Is Riding on Helus Pharma's Phase Three Readout? - Kalkine Media
Helus Pharma remains a buy ahead of key Phase 3 data for HLP003 expected in late 2026. - Pluang
Helus Pharma: A Buy Ahead Of The HLP003 Phase 3 Readout (NASDAQ:HELP) - Seeking Alpha
Helus Pharma (DB:R7E0)Rendimiento de beneficios e ingresos - Simply Wall Street
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Connect Biopharma Holdings (CNTB) and Helus Pharma (HELP) - The Globe and Mail
Cybin D/B/A Helus Pharma (HELP) Options Chain - Yahoo! Finance Canada
Helus Pharma (NEOE:HELP)Análisis de acciones - Simply Wall Street
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance Singapore
Helus Pharma (HELP) will discuss depression and anxiety drugs at its investor webcast - Stock Titan
H.C. Wainwright reiterates Helus Pharma stock rating at buy - Investing.com
Helus Pharma to present updates on depression a... - Pluang
Helus Pharma to Host Investor Presentation on October 21, 2026 Highlighting HLP003 and HLP004 Development Programs - Quiver Quantitative
Helus Pharma to Host Investor Presentation on October 21, 2026Thu, 10/08/202607:30 - Helus Pharma
Helus Pharma Stock Under Pressure: Clinical Risk and Bearish Momentum Raise Correction Concerns - kalkine.ca
Helus Pharma Stock Drops 7.29% as Volatility Builds Ahead of Pivotal Phase 3 APPROACH Readout for HLP003 (CN:HELP) - kalkine.ca
Form 6-K Helus Pharma Inc. For: Oct 01 - StreetInsider
[6-K] CYBIN INC. Current Report (Foreign Issuer) - Stock Titan
Helus Pharma Stock Faces Renewed Pressure as Bearish Momentum Raises Correction Risk — Healthcare - kalkine.ca
Helus Pharma (NasdaqGM:HELP) Stock Forecast & Analyst Predictions - Simply Wall Street
HELPInterventional Psychiatry And Clinic Partnerships Will Support Long Term Psychedelic Treatment Adoption - Simply Wall Street
Helus Pharma Inc.: Target Price Consensus and Analysts Recommendations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma Inc.: Financial Data Forecasts Estimates and Expectations | CLXPF | CA4234921076 - marketscreener.com
Helus Pharma (NasdaqGM:HELP)Rendimiento de beneficios e ingresos - Simply Wall Street
Helus Pharma Inc. (HELP) análisis del equipo directivo y de gestión - Simply Wall Street
No shareholder action is needed as Cybin (HELP) becomes Helus Pharma and keeps its ticker. - Stock Titan
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Canada
Form 4 Helus Pharma Inc. For: 1 October By Investing.com - Investing.com Nigeria
Helus Pharma Finalizes Legal Name Change as It Prepares for Commercial Push - TipRanks
Helus Pharma (HELP) Officially Changes Legal Name from Cybin Inc. on October 1, 2026 - GuruFocus
Cybin rebrands to Helus Pharma, ticker symbol unchanged - Investing.com
CapEx per share of Helus Pharma Inc. – HAN:R7E - TradingView
Helus Pharma Announces Completion of Legal Name ChangeThu, 10/01/202607:30 - Helus Pharma
Helus Pharma Announces Completion of Legal Name Change - Yahoo Finance
Cybin Changes Legal Name to Helus Pharma - Yahoo Finance
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - Yahoo Finance
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - quiverquant.com
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - Yahoo Finance
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026Mon, 09/21/202607:30 - Helus Pharma
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma at Cantor conference: phase III readout in focus - investing.com
Helus Pharma at Cantor conference: phase III readout in focus - Investing.com India
Cybin Executive Chair Eric H. L. So Acquires 100,000 Shares in Voluntary Filing - Kalkine Media
CYBIN INC. (NASDAQ: HELP) Executive Eric So Holds Sole Authority Over 4.37 Million Shares - Kalkine Media
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - MarketBeat
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
4.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):